What Are Unicycive Therapeutics Inc.'s Key Financial Figures?
| Fiscal year | FY2023 ended December 31, 2023 | FY2022 ended December 31, 2022 |
|---|---|---|
| Revenue | $675,000 | $951,000 |
| Operating income | -$21 million | -$18 million |
| Operating margin | -3077.6% | -1898.2% |
| Net income | -$31 million | -$18 million |
| Net margin | -4525.0% | -1898.8% |
| Operating cash flow | -$18 million | -$16 million |
| Capital expenditures | $12,000 | $2,000 |
| Free cash flow | -$18 million | -$16 million |
Operating margin narrowed by 1179.4 percentage points between fiscal 2022 and 2023, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$18 million against net income of -$31 million; cash generation covered reported earnings.
What Does Unicycive Therapeutics Inc.'s Balance Sheet Show?
| Cash and cash equivalents | $10 million |
|---|---|
| Long-term debt | Not reported |
| Total assets | $14 million |
| Total liabilities | $18 million |
| Shareholders' equity | -$4 million |
| Current ratio | 0.8x |
Balance sheet values are as of the end of fiscal 2023. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions.
Where These Numbers Come From
Every figure on this page is a value Unicycive Therapeutics Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001213900-25-025828 for fiscal year 2023). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
What was Unicycive Therapeutics Inc.'s revenue in fiscal 2023?
Unicycive Therapeutics Inc. reported revenue of $675,000 for the fiscal year ended December 31, 2023, according to its SEC filings.
What is Unicycive Therapeutics Inc.'s operating margin?
Unicycive Therapeutics Inc.'s operating margin was -3077.6% in fiscal 2023: operating income of -$21 million on revenue of $675,000.
How much free cash flow did Unicycive Therapeutics Inc. generate?
Operating cash flow of -$18 million less capital expenditures of $12,000 gives free cash flow of -$18 million for fiscal 2023.